NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Given Consensus Recommendation of “Moderate Buy” by Brokerages

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) has been given a consensus rating of “Moderate Buy” by the twelve research firms that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, nine have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $48.00.

Several brokerages have weighed in on NAMS. Truist Financial assumed coverage on NewAmsterdam Pharma in a research note on Wednesday. They issued a “buy” rating and a $57.00 target price on the stock. The Goldman Sachs Group increased their price target on NewAmsterdam Pharma from $30.00 to $37.00 and gave the stock a “neutral” rating in a report on Tuesday, December 2nd. Leerink Partners reiterated an “outperform” rating and issued a $55.00 price objective on shares of NewAmsterdam Pharma in a research report on Tuesday, January 6th. Stifel Nicolaus boosted their price objective on shares of NewAmsterdam Pharma from $44.00 to $50.00 and gave the company a “buy” rating in a research note on Tuesday, December 16th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of NewAmsterdam Pharma in a research report on Thursday, February 19th.

Insider Activity

In other NewAmsterdam Pharma news, insider Johannes Jacob Piete Kastelein sold 104,467 shares of NewAmsterdam Pharma stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $30.30, for a total value of $3,165,350.10. Following the sale, the insider owned 69,302 shares of the company’s stock, valued at approximately $2,099,850.60. The trade was a 60.12% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Michael H. Davidson sold 443,707 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $33.25, for a total value of $14,753,257.75. Following the transaction, the chief executive officer owned 174,144 shares in the company, valued at $5,790,288. The trade was a 71.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 1,466,933 shares of company stock valued at $48,448,017. 20.84% of the stock is owned by insiders.

Institutional Trading of NewAmsterdam Pharma

A number of institutional investors have recently modified their holdings of NAMS. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in NewAmsterdam Pharma in the first quarter worth $610,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in NewAmsterdam Pharma by 13.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 288,134 shares of the company’s stock valued at $5,898,000 after acquiring an additional 34,563 shares during the period. Bank of New York Mellon Corp purchased a new stake in shares of NewAmsterdam Pharma during the 2nd quarter worth $6,392,000. Geode Capital Management LLC grew its stake in shares of NewAmsterdam Pharma by 15.9% during the 2nd quarter. Geode Capital Management LLC now owns 99,457 shares of the company’s stock worth $1,800,000 after purchasing an additional 13,629 shares during the period. Finally, Handelsbanken Fonder AB grew its stake in shares of NewAmsterdam Pharma by 31.4% during the 2nd quarter. Handelsbanken Fonder AB now owns 341,600 shares of the company’s stock worth $6,186,000 after purchasing an additional 81,600 shares during the period. 89.89% of the stock is currently owned by hedge funds and other institutional investors.

NewAmsterdam Pharma Stock Performance

Shares of NAMS opened at $28.94 on Friday. NewAmsterdam Pharma has a fifty-two week low of $14.06 and a fifty-two week high of $42.00. The firm has a 50-day simple moving average of $32.63 and a 200-day simple moving average of $33.54. The company has a market capitalization of $3.33 billion, a price-to-earnings ratio of -16.73 and a beta of 0.04.

NewAmsterdam Pharma (NASDAQ:NAMS) last issued its quarterly earnings results on Wednesday, February 18th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.23). The company had revenue of $0.03 million during the quarter, compared to analyst estimates of $0.92 million. NewAmsterdam Pharma had a negative net margin of 906.22% and a negative return on equity of 26.67%. Equities research analysts forecast that NewAmsterdam Pharma will post -1.75 EPS for the current year.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.